BioVie Inc. presented Phase 2 trial results showing that bezisterim significantly improved both motor and non-motor symptoms in early Parkinson’s patients with elevated inflammation. The SUNRISE-PD trial involved 57 patients treated for 12 weeks, with those having higher baseline inflammation showing the strongest response. Bezisterim was well tolerated and may offer a new treatment option addressing both symptom types and potentially slowing disease progression. Further studies, including a Phase 3 trial, are planned to confirm these findings.
BioVie’s presentation on bezisterim in Parkinson’s disease offers context for health-sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 20, 2026 19:03 WIB: Out of 150 priced US health-sector stocks, 81 rose and 62 fell. Notable movers include RXRX at USD 3.54 with a 1-day change of -1.94% and Pluang order activity showing 72% Sell / 28% Buy, ALC at USD 67.41 with a 1-day change of +1.94% and 0% Sell / 100% Buy order activity, and NUVB at USD 4.40 with a 1-day change of -1.79%. Typical hold times on Pluang range from 11 to 71 days among these stocks.
Hershey is preparing to announce its Q3 earnings on October 29, with analysts forecasting earnings per share (EPS) of $2.12, a 63% increase from last year, and revenue of $3.25 billion, up 2.3%. The company has shown strong recent performance, with Q...
3M reported strong Q3 2026 earnings with adjusted EPS of $2.50, beating estimates of $2.38, and GAAP profit rising to $1.37 billion from $834 million a year earlier. Sales reached $6.6 billion, slightly below estimates, but showed 3.3% organic growth...
Alaska Air Group is set to report Q3 2026 earnings with analysts expecting a 66.7% drop in earnings per share to $0.35, despite a 14.5% increase in revenue to $4.31 billion driven by strong travel demand. Passenger revenue is forecast to rise 10.2%, ...
Baba, an applied AI company focused on modernizing Medicare and Medicaid care, has raised $40 million in a Series A funding round led by FirstMark Capital, with participation from CVS Health Ventures and others. The funding will help Baba expand its ...
Richard Campbell-Breeden, a seasoned investment banker with 37 years of experience including 27 years at Goldman Sachs, has joined SEDA Experts LLC as Managing Director. His expertise in mergers and acquisitions, corporate finance, and governance wil...
